Global Clinical Trials Market Forecast
- Clinical trials market size to reach approximately US$79.9 Bn in 2030, up from US$52.5 Bn registered in 2022
- Market valuation poised to witness a CAGR of 6.2% during 2023 - 2030
Quick Report Digest
- The increasing prevalence of chronic diseases, demanding the development of novel drugs and therapies to improve the state of a patient with a chronic illness, is a significant growth driver for the clinical trials market.
- It is also anticipated that the rising R&D expenditures by major market players will have a substantial impact on the industry's expansion.
- In 2022, the phase III category dominated the industry. The main factor contributing to phase 3's significant market share is its widespread implementation. Over the estimated time, additional variables such as high costs and the growing tendency of outsourcing are anticipated to increase demand.
- In terms of market share for clinical trials globally, the interventional segment is anticipated to dominate. The significant revenue share of interventional studies is mostly due to the rising prevalence of new viral illnesses and ongoing technological advancements in clinical trials.
- In 2022, the oncology category controlled the market. The main causes of oncology's large share include ongoing research into cancer treatments and the rising need for precision medicine.
- The clinical trial data management services category is highly prevalent in the market for clinical trials. The primary drivers influencing sector growth include the increasing number of clinical trials, technical advancements in clinical trial monitoring, and strict regulations pertaining to data management & security.
- The North American region is anticipated to account for the largest share of the global clinical trials market. The rise in R&D in this area and the deployment of new technology in clinical research are both responsible for this.
- The market for clinical trials is expanding in Asia Pacific. A growing number of biotechnology businesses selected the Asia Pacific region for COVID-19 investigations because of the region's sizable patient pool and efficient procedures.
A Look Back and a Look Forward - Comparative Analysis
The ongoing efforts made by pharmaceutical, biotechnology, and medical device businesses for breakthroughs are what primarily fuel the clinical trial market. The globalisation of clinical trials, the quick development of related technologies, and the rising demand for CROs to perform clinical trials are further factors influencing the market's growth.
The market witnessed staggered growth during the historical period 2018 – 2022. The healthcare sector was under tremendous strain as a result of the growing demand for new medications to treat chronic illnesses like cancer, respiratory problems, diabetes, cardiovascular diseases, and others.
The market was being driven by the COVID-19 pandemic and the rising demand for creating an effective therapy. The measures undertaken by the government in various regions have also helped the market expand.
To satisfy the rising need for the treatment of chronic diseases, registration of trials has been expanding at a notable rate each year. The rise of the clinical trials business will be anchored by the dramatically rising number of projects launched by numerous government and non-government organisations. The increasing funding for numerous clinical trials from government funding organisations and pharmaceutical corporations will also impact the dynamics of the sector.
Key Growth Determinants
- Growing Disease Variation and Prevalence
The clinical trial market is predicted to continue to grow as disease incidence and prevalence continue to rise. The illness profiles of the global population are diverse, with rising nations having the most diversified disease profiles. This is anticipated to help clinical trials for new or rare diseases that would not have otherwise secured sponsors.
If there were more patients with a certain issue, biopharmaceutical companies would be encouraged to increase their participation in clinical trials for that disease area. A diverse population would also make patient recruiting simpler and the clinical trial process go more quickly.
In the US, uncommon diseases are referred to as "Orphan diseases," and biopharmaceutical companies that sponsor clinical trials for Orphan drugs are compensated for their efforts. This trend is most likely to benefit clinical trials for uncommon diseases, growing the market for clinical trials worldwide.
- Rapid Shift Toward Personalised Medicine
In the clinical trial market, a positive paradigm shift toward personalised treatment is anticipated. The traditional clinical trial procedure involves thousands of participants, whereas personalised medicine will concentrate solely on the impact of medications on specific patients over a predetermined length of time.
Due to the conventional clinical trial methodology, very few drugs that are still in the development phase of testing complete all rounds. Drugs that are now in development but will never be used because of the "one size fits all" approach are being prevented from entering the market.
The number of medications passing all stages of the clinical trial procedure is anticipated to rise with the application of pharmacogenetics in the process. It is anticipated that the move towards personalised medicine would enhance the use of pharmacogenetics throughout the clinical trial phase, hence expanding the available medication pool.
The biopharmaceutical industry is anticipated to increase its investment in the clinical trial stage as a result of this trend.
- Growing Drug Pipelines, and Investments in Pharmaceutical R&D
Companies in the pharmaceutical, biopharmaceutical, and medical device sectors invest heavily in the creation of cutting-edge medicines and technologies. With a focus on creating both high-quality and unique products, this industry invests heavily in R&D.
Leading pharmaceutical businesses are improving R&D efficiency, according to recent trends, by making significant R&D investments for long-term returns and encouraging joint research efforts.
A shift towards comprehensive integrated or functionally outsourced services covering the entire process of drug discovery and development, from early-stage development to late-stage development phase, is being driven by the rising R&D investments within the pharmaceutical and biopharmaceutical sectors. A sizable number of pharmaceutical and biopharmaceutical businesses currently outsource their testing functions during R&D to CROs in order to increase profitability, adhere to strict drug development timeframes, and achieve cost reductions.
Recent collaborations between well-known pharmaceutical companies, and CROs make this tendency particularly clear. Throughout the forecast period, these trends are anticipated to dominate the market.
Major Growth Barriers
- Patient Recruitment and Retention
Finding the correct patient population is challenging because attention has turned to hereditary and rare illnesses. Additionally, the lack of patient understanding of clinical trials makes it challenging for CROs to operate. Improper patient recruitment may influence the scientific and economic viability.
Patients' concerns about side effects, illiteracy, language barriers for geographically specialised clinical trials, and the lack of documentation of the consent procedure are other reasons that contribute to poor patient recruitment.
- Lack of Skilled Workforce
Clinical research organisations (CROs) have difficulty attracting and retaining qualified personnel. For competent and experienced scientists, they must compete with pharmaceutical businesses, biotech companies, manufacturers of medical equipment, and academic research institutions. These businesses must provide greater salaries and benefits in order to compete effectively.
However, this may have an impact on their earnings and performance, particularly for small-scale clinical trial service providers. The adoption of new technologies and processes may be hampered by this talent gap, which could also limit industry expansion in the years to come.
Key Trends and Opportunities to Look at
- Augmenting R&D Investments by Pharma and Biotech Companies
The development of novel technology and medicines continues to get significant funding from numerous medical device, pharmaceutical, and biopharmaceutical businesses. Particularly in the pharmaceutical industry, significant investments have been made in R&D projects for the creation of innovative treatments.
Pharmaceutical and biotechnology businesses are putting more of an emphasis on increasing their R&D productivity by funding R&D. In order to execute these trials quickly and smoothly, many companies have started outsourcing their R&D activities to CRO firms.
- Favourable Outlook for Biologics and Biosimilars
In recent years, the fields of pharmaceuticals and biotechnology have expanded quickly. R&D initiatives focused on developing novel pharmaceuticals and biological substances for treating a variety of ailments have received notable expenditures. Numerous novel medications and biologics are undergoing clinical trials right now.
The need for clinical trial services is anticipated to increase significantly due to the ongoing influx of novel pharmaceutical items in the pipeline. The COVID-19 effect resulted in a general decline in US FDA approvals in 2022, but the biologics industry was untouched, recording the approval of 15 novel compounds and retaining momentum from past years.
- Increasing Collaborations in Biomedical Research
The market for clinical trials worldwide is anticipated to be further boosted by the trend towards combination studies and collaborations in clinical trials. Biopharmaceutical businesses are now forging alliances with one another to pool resources and spread the risk of high costs as a result of the high cost of medication development.
How Does the Regulatory Scenario Shape this Industry?
The universal adoption of best practices raises clinical data credibility and makes it acceptable to regulatory bodies all around the world. The European Union, Japan, the United States, Australia, Canada, the Nordic nations, and the World Health Organisation provide a uniform standard under International Conference of Harmonisation of Technical Requirements for Registration of Medicines and Devices for Human Use.
The ICH-Efficacy recommendations concern clinical trials involving human subjects. The Declaration of Helsinki (DoH), a statement of ethical principles, was created by the World Medical Association (WMA) to serve as a guide for doctors and other individuals involved in medical research involving human people.
Furthermore, in the U.S., U.S. pharmaceutical and medical device businesses perform clinical trials as part of an application to the FDA for permission to market a medicine or device. Unless the product is exempt from this requirement, medical device businesses looking to sell a Class I or Class II medical device need only submit a 510(k) pre-market notification. A clinical study must be done in accordance with an Investigational Drug Exemption (IDE) in support of a Pre-Market Approval application (PMA) for a Class III device, which is subject to the toughest regulation.
Additionally, in India, the Ministry of Health, in collaboration with the DCGI and the ICMR, developed Good Clinical Practises (GCP-India) standards as an ethical and scientific quality standard for the design and conduct of human subjects trials.
Fairfield’s Ranking Board
Top Segments
- Phase III Category Continues to Dominate
With a share of sales of 53.5% of the global market in 2022, the Phase III sector had the highest revenue. Phase III trials, which contain the largest subject populations and the highest costs, are the reason for this. Phase III also necessitates a larger patient base and frequently a longer duration of therapy.
Furthermore, the phase II category is projected to experience the fastest market growth. The two steps of this study are the first stage, which entails investigating a variety of doses and performing efficacy tests, and the second stage, which entails choosing the dose. Due to the several drugs and vaccines that are currently in Phase II and are suggested for the treatment of COVID-19, the segment will grow.
- Interventional Studies Category Spearheads
In 2022, the interventional studies dominated the industry. This method is one of the most widely used in clinical studies. As of May 2020, the bulk of these studies were interventional behavioral, clinical procedure, and device investigations, with the remainder being trialed for drugs or biologics. At that time, 79.0% of all registered studies were interventional studies.
The expanded access category is anticipated to grow substantially throughout the projected period. There may be a means for people with severe sickness problems to receive therapy outside of the trial if there are no appropriate medicines accessible. The extended access trials segment is expected to be driven by growing innovation in clinical trial methodologies.
- Oncology Remains the Leading Segment
The oncology segment led the market in 2022 because of its large revenue. The segment is expanding as a result of rising cancer treatment drug approval rates and rising need for efficient cancer medicines. Clinical development has mostly focused on non-small cell lung cancer (NSCLC) and breast cancer, among the several oncology indications.
The cardiovascular category is expected to experience the fastest growth within the forecast time frame. Due to the massive investment being made in R&D in this industry as a result of the expanding prevalence and global demand for cost-effective drugs, more than 190 pharmaceuticals are now being developed. It is anticipated that rising government R&D spending will increase demand for affordable pharmaceuticals in low- and middle-income nations, supporting market expansion.
- Demand for Clinical Trial Data Management Services Maximum
In 2022, the clinical trial data management services category led the market growth. The demand for clinical data management systems is anticipated to increase as there are more clinical trials conducted, particularly in the Asia Pacific area. The demand for quick and cutting-edge technologies to perform clinical trials is growing as the number of trials rises.
As a result, clinical data management tools are utilised in clinical research to manage such large amounts of data because they are one of the sponsors' most valuable assets. Moreover, the laboratory services category is expected to grow fastest in the clinical trials market during the forecast period.
The sector is growing as a result of factors like the growing cases of chronic diseases and the rising demand for early diagnostic tests. Additionally, it is projected that during the forecast period, quick developments in sample preparation and data management will propel sector growth.
Regional Frontrunners
The US Secures Leadership Position for North America
Because of factors like the pharmaceutical industry's high R&D spending, the presence of well-established players, the region's robust regulatory structure, the rising prevalence of diseases, and the sizeable contribution of the United States, the North American region is anticipated to contribute to the market growth during the study period significantly.
Additionally, the support provided by the governments of the region's nations is fostering market expansion. The participation of the region's top market players in the development of new drugs and devices is a second factor that is projected to boost market expansion in the area.
Asia Pacific Fastest on the Back of a Large Accessible Patient Pool for Clinical Trial Participation
Asia Pacific, on the other hand, is predicted to grow at the fastest pace during the forecast period. This is because a sizable patient pool is easily accessible, making it simpler to find participants for clinical trials. Due to their excellent quality and quick turnaround, "Novotech," Asia Pacific's largest and most seasoned biotech CRO, has seen a rise in requests for studies from biotechnology sponsors.
There is potential for the market to expand due to the region's growing need for people with obesity, cancer, and cardiovascular diseases. The rise in ageing population, and widespread age-related health difficulties are to blame for the market expansion in nations like China, and Japan. The market in this area is expanding at a faster rate thanks to rising government and private organisation funding for the cheap delivery of medications.
Fairfield’s Competitive Landscape Analysis
The global clinical trials market is a congested industry with few significant companies operating worldwide. To increase their global footprint, the major firms are launching new items and enhancing their distribution networks. In addition, Fairfield Market Research anticipates that during the next few years, there will be further market consolidation.
Who are the Leaders in the Global Clinical Trials Space?
- Eli Lilly and Company
- Syneos Health
- Pharmaceutical Product Development (PPD)
- Novo Nordisk A/S
- Icon plc.
- Charles River Laboratories
- Parexel International Corporation
- WuXi Apptec
- Medpace Holdings, Inc.
- KCR Pharmaceuticals Pvt. Ltd.
- Pharmaceutical Solutions Industry Ltd. (PSI).
- Pfizer
- Thermo Fisher Scientific Inc.
- Sanofi SA
Significant Company Developments
New Product Launches
- March 2023: Assentia launched technology systems to assist clinical trial payments. The company announced the launching of GrantPay and GrantPact, two technology platforms aimed at this objective. GrantPay can deliver investigator site payments in multiple currencies and across the globe. GrantPact is a platform for negotiating and tracking worldwide clinical trial contracts.
- October 2022: Thermo Fisher Scientific Inc., a global leader in science service, has launched the PPD DCT Network to assist global investigators and research locations engaging in decentralised clinical trials (DCTs) for pharmaceutical and biotech companies. Investigators and locations will receive practical DCT training through the DCT network, which will lead to network membership.
Distribution Agreements
- March 2023: LEO Pharma, a global leader in medical dermatology, and ICON plc announced an agreement that will allow LEO Pharma to expand its patient-centric and cost-effective clinical trial execution, supporting the company's overall goal of building one of the industry's most effective and efficient clinical portfolio execution organisations.
- February 2023: Syneos Health and Haystack Health have formed a strategic partnership to increase clinical trial patient identification and enrollment. The collaboration will use artificial intelligence (AI) to speed up clinical trials and provide useful research tools and workflow efficiencies to sponsors and sites. These techniques result in shorter timelines and increased patient recruitment.
- January 2023: Rznomics has announced a collaboration with Charles River Laboratories International, Inc., a contract development and manufacturing organisation (CDMO) for viral vectors. Rznomics plans to commence clinical development of their RNA-based anticancer gene therapy in patients with liver cancer using Charles River's viral vector CDMO expertise.
An Expert’s Eye
Demand and Future Growth
As per Fairfield’s Analysis, the industry is being driven by an increase in the prevalence of chronic disorders. The rising demand for a complete cure for disease coupled with the rising participation of patients in trials may result in a growth in clinical trials, where clinical trial data management services are favoured in large quantities, increasing the need for clinical trials.
Furthermore, technological developments have greatly aided the growth and development of various clinical trials. However, the clinical trials market is expected to face considerable challenges because of the high cost associated with trials.
Supply Side of the Market
According to our analysis, the manufacturers present in the clinical trial market are focusing on enhancing the trial credibility and acceptance by introducing new techniques, especially in the interventional category, which will help the end users accept the data from the trial with absolute faith. The US is the leading region in the clinical trial market with respect to the growing number of trials in the region.
The National Library of Medicine reported 38,837 active clinical trials in the United States in January 2023, the most of any country. In addition, the region's expanding number of CROs is contributing to increased demand for clinical trial facilities. As of 2023, there are 2,823 Contract Research Organisations enterprises in the United States, a 0.9% growth from 2022.
Along with this, China in the Asia Pacific region is growing at a faster rate due to the rising Western influence in the nation as a result of its larger population. Western commercial enterprises' involvement in trials conducted in China has gradually increased over the last decade, from around 100 trials per year in 2010 to around 350 in 2021.
In addition, the region's expanding number of CROs is contributing to increased demand for clinical trial facilities. There are currently around 300 CROs in China that provide preclinical and clinical research services to MNCs, local enterprises, and other R&D organisations.
Global Clinical Trials Market is Segmented as Below:
By Phase:
- Phase I
- Phase II
- Phase III
- Phase IV
By Study Design:
- Interventional
- Observational
- Expanded Access
By Indication:
- Autoimmune/Inflammation
- Rheumatoid arthritis
- Multiple Sclerosis
- Osteoarthritis
- Irritable Bowel Syndrome (IBS)
- Others
- Pain Management
- Chronic Pain
- Acute Pain
- Oncology
- Blood Cancer
- Solid Tumours
- Other
- CNS Condition
- Epilepsy
- Parkinson's Disease (PD)
- Huntington's Disease
- Stroke
- Traumatic Brain Injury (TBI)
- Amyotrophic Lateral Sclerosis (ALS)
- Muscle Regeneration
- Others
- Diabetes
- Obesity
- Cardiovascular
- Others
By Service Type:
- Protocol Designing
- Site Identification
- Patient Recruitment
- Laboratory Services
- Bioanalytical Testing Services
- Clinical Trial Data Management Services
- Others
By Geographic Coverage:
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
1. Executive Summary
1.1. Global Clinical Trials Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2022
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. Covid-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Clinical Trials Market Outlook, 2018 - 2030
3.1. Global Clinical Trials Market Outlook, by Phase, Value (US$ Bn), 2018 - 2030
3.1.1. Key Highlights
3.1.1.1. Phase I
3.1.1.2. Phase II
3.1.1.3. Phase III
3.1.1.4. Phase IV
3.2. Global Clinical Trials Market Outlook, by Study Design, Value (US$ Bn), 2018 - 2030
3.2.1. Key Highlights
3.2.1.1. Interventional
3.2.1.2. Observational
3.2.1.3. Expanded Access
3.3. Global Clinical Trials Market Outlook, by Indication, Value (US$ Bn), 2018 - 2030
3.3.1. Key Highlights
3.3.1.1. Autoimmune/Inflammation
3.3.1.1.1. Rheumatoid arthritis
3.3.1.1.2. Multiple Sclerosis
3.3.1.1.3. Osteoarthritis
3.3.1.1.4. Irritable Bowel Syndrome (IBS)
3.3.1.1.5. Others
3.3.1.2. Pain Management
3.3.1.2.1. Chronic Pain
3.3.1.2.2. Acute Pain
3.3.1.3. Oncology
3.3.1.3.1. Blood Cancer
3.3.1.3.2. Solid Tumors
3.3.1.3.3. Other
3.3.1.4. CNS Condition
3.3.1.4.1. Epilepsy
3.3.1.4.2. Parkinson's Disease (PD)
3.3.1.4.3. Huntington's Disease
3.3.1.4.4. Stroke
3.3.1.4.5. Traumatic Brain Injury (TBI)
3.3.1.4.6. Amyotrophic Lateral Sclerosis (ALS)
3.3.1.4.7. Muscle Regeneration
3.3.1.4.8. Others
3.3.1.5. Diabetes
3.3.1.6. Obesity
3.3.1.7. Cardiovascular
3.3.1.8. Others
3.4. Global Clinical Trials Market Outlook, by Service Type, Value (US$ Bn), 2018 - 2030
3.4.1. Key Highlights
3.4.1.1. Protocol Designing
3.4.1.2. Site Identification
3.4.1.3. Patient Recruitment
3.4.1.4. Laboratory Services
3.4.1.5. Bioanalytical Testing Services
3.4.1.6. Clinical Trial Data Management Services
3.4.1.7. Others
3.5. Global Clinical Trials Market Outlook, by Region, Value (US$ Bn), 2018 - 2030
3.5.1. Key Highlights
3.5.1.1. North America
3.5.1.2. Europe
3.5.1.3. Asia Pacific
3.5.1.4. Latin America
3.5.1.5. Middle East & Africa
4. North America Clinical Trials Market Outlook, 2018 - 2030
4.1. North America Clinical Trials Market Outlook, by Phase, Value (US$ Bn), 2018 - 2030
4.1.1. Key Highlights
4.1.1.1. Phase I
4.1.1.2. Phase II
4.1.1.3. Phase III
4.1.1.4. Phase IV
4.2. North America Clinical Trials Market Outlook, by Study Design, Value (US$ Bn), 2018 - 2030
4.2.1. Key Highlights
4.2.1.1. Interventional
4.2.1.2. Observational
4.2.1.3. Expanded Access
4.3. North America Clinical Trials Market Outlook, by Indication, Value (US$ Bn), 2018 - 2030
4.3.1. Key Highlights
4.3.1.1. Autoimmune/Inflammation
4.3.1.1.1. Rheumatoid arthritis
4.3.1.1.2. Multiple Sclerosis
4.3.1.1.3. Osteoarthritis
4.3.1.1.4. Irritable Bowel Syndrome (IBS)
4.3.1.1.5. Others
4.3.1.2. Pain Management
4.3.1.2.1. Chronic Pain
4.3.1.2.2. Acute Pain
4.3.1.3. Oncology
4.3.1.3.1. Blood Cancer
4.3.1.3.2. Solid Tumors
4.3.1.3.3. Other
4.3.1.4. CNS Condition
4.3.1.4.1. Epilepsy
4.3.1.4.2. Parkinson's Disease (PD)
4.3.1.4.3. Huntington's Disease
4.3.1.4.4. Stroke
4.3.1.4.5. Traumatic Brain Injury (TBI)
4.3.1.4.6. Amyotrophic Lateral Sclerosis (ALS)
4.3.1.4.7. Muscle Regeneration
4.3.1.4.8. Others
4.3.1.5. Diabetes
4.3.1.6. Obesity
4.3.1.7. Cardiovascular
4.3.1.8. Others
4.4. North America Clinical Trials Market Outlook, by Service Type, Value (US$ Bn), 2018 - 2030
4.4.1. Key Highlights
4.4.1.1. Protocol Designing
4.4.1.2. Site Identification
4.4.1.3. Patient Recruitment
4.4.1.4. Laboratory Services
4.4.1.5. Bioanalytical Testing Services
4.4.1.6. Clinical Trial Data Management Services
4.4.1.7. Others
4.4.2. BPS Analysis/Market Attractiveness Analysis
4.5. North America Clinical Trials Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
4.5.1. Key Highlights
4.5.1.1. U.S. Clinical Trials Market by Phase, Value (US$ Bn), 2018 - 2030
4.5.1.2. U.S. Clinical Trials Market by Study Design, Value (US$ Bn), 2018 - 2030
4.5.1.3. U.S. Clinical Trials Market by Indication, Value (US$ Bn), 2018 - 2030
4.5.1.4. U.S. Clinical Trials Market by Service Type, Value (US$ Bn), 2018 - 2030
4.5.1.5. Canada Clinical Trials Market by Phase, Value (US$ Bn), 2018 - 2030
4.5.1.6. Canada Clinical Trials Market by Study Design, Value (US$ Bn), 2018 - 2030
4.5.1.7. Canada Clinical Trials Market by Indication, Value (US$ Bn), 2018 - 2030
4.5.1.8. Canada Clinical Trials Market by Service Type, Value (US$ Bn), 2018 - 2030
4.5.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Clinical Trials Market Outlook, 2018 - 2030
5.1. Europe Clinical Trials Market Outlook, by Phase, Value (US$ Bn), 2018 - 2030
5.1.1. Key Highlights
5.1.1.1. Phase I
5.1.1.2. Phase II
5.1.1.3. Phase III
5.1.1.4. Phase IV
5.2. Europe Clinical Trials Market Outlook, by Study Design, Value (US$ Bn), 2018 - 2030
5.2.1. Key Highlights
5.2.1.1. Interventional
5.2.1.2. Observational
5.2.1.3. Expanded Access
5.3. Europe Clinical Trials Market Outlook, by Indication, Value (US$ Bn), 2018 - 2030
5.3.1. Key Highlights
5.3.1.1. Autoimmune/Inflammation
5.3.1.1.1. Rheumatoid arthritis
5.3.1.1.2. Multiple Sclerosis
5.3.1.1.3. Osteoarthritis
5.3.1.1.4. Irritable Bowel Syndrome (IBS)
5.3.1.1.5. Others
5.3.1.2. Pain Management
5.3.1.2.1. Chronic Pain
5.3.1.2.2. Acute Pain
5.3.1.3. Oncology
5.3.1.3.1. Blood Cancer
5.3.1.3.2. Solid Tumors
5.3.1.3.3. Other
5.3.1.4. CNS Condition
5.3.1.4.1. Epilepsy
5.3.1.4.2. Parkinson's Disease (PD)
5.3.1.4.3. Huntington's Disease
5.3.1.4.4. Stroke
5.3.1.4.5. Traumatic Brain Injury (TBI)
5.3.1.4.6. Amyotrophic Lateral Sclerosis (ALS)
5.3.1.4.7. Muscle Regeneration
5.3.1.4.8. Others
5.3.1.5. Diabetes
5.3.1.6. Obesity
5.3.1.7. Cardiovascular
5.3.1.8. Others
5.4. Europe Clinical Trials Market Outlook, by Service Type, Value (US$ Bn), 2018 - 2030
5.4.1. Key Highlights
5.4.1.1. Protocol Designing
5.4.1.2. Site Identification
5.4.1.3. Patient Recruitment
5.4.1.4. Laboratory Services
5.4.1.5. Bioanalytical Testing Services
5.4.1.6. Clinical Trial Data Management Services
5.4.1.7. Others
5.4.2. BPS Analysis/Market Attractiveness Analysis
5.5. Europe Clinical Trials Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
5.5.1. Key Highlights
5.5.1.1. Germany Clinical Trials Market by Phase, Value (US$ Bn), 2018 - 2030
5.5.1.2. Germany Clinical Trials Market by Study Design, Value (US$ Bn), 2018 - 2030
5.5.1.3. Germany Clinical Trials Market by Indication, Value (US$ Bn), 2018 - 2030
5.5.1.4. Germany Clinical Trials Market by Service Type, Value (US$ Bn), 2018 - 2030
5.5.1.5. U.K. Clinical Trials Market by Phase, Value (US$ Bn), 2018 - 2030
5.5.1.6. U.K. Clinical Trials Market by Study Design, Value (US$ Bn), 2018 - 2030
5.5.1.7. U.K. Clinical Trials Market by Indication, Value (US$ Bn), 2018 - 2030
5.5.1.8. U.K. Clinical Trials Market by Service Type, Value (US$ Bn), 2018 - 2030
5.5.1.9. France Clinical Trials Market by Phase, Value (US$ Bn), 2018 - 2030
5.5.1.10. France Clinical Trials Market by Study Design, Value (US$ Bn), 2018 - 2030
5.5.1.11. France Clinical Trials Market by Indication, Value (US$ Bn), 2018 - 2030
5.5.1.12. France Clinical Trials Market by Service Type, Value (US$ Bn), 2018 - 2030
5.5.1.13. Italy Clinical Trials Market by Phase, Value (US$ Bn), 2018 - 2030
5.5.1.14. Italy Clinical Trials Market by Study Design, Value (US$ Bn), 2018 - 2030
5.5.1.15. Italy Clinical Trials Market by Indication, Value (US$ Bn), 2018 - 2030
5.5.1.16. Italy Clinical Trials Market by Service Type, Value (US$ Bn), 2018 - 2030
5.5.1.17. Russia Clinical Trials Market by Phase, Value (US$ Bn), 2018 - 2030
5.5.1.18. Russia Clinical Trials Market by Study Design, Value (US$ Bn), 2018 - 2030
5.5.1.19. Russia Clinical Trials Market by Indication, Value (US$ Bn), 2018 - 2030
5.5.1.20. Russia Clinical Trials Market by Service Type, Value (US$ Bn), 2018 - 2030
5.5.1.21. Rest of Europe Clinical Trials Market by Phase, Value (US$ Bn), 2018 - 2030
5.5.1.22. Rest of Europe Clinical Trials Market by Study Design, Value (US$ Bn), 2018 - 2030
5.5.1.23. Rest of Europe Clinical Trials Market by Indication, Value (US$ Bn), 2018 - 2030
5.5.1.24. Rest of Europe Clinical Trials Market by Service Type, Value (US$ Bn), 2018 - 2030
5.5.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Clinical Trials Market Outlook, 2018 - 2030
6.1. Asia Pacific Clinical Trials Market Outlook, by Phase, Value (US$ Bn), 2018 - 2030
6.1.1. Key Highlights
6.1.1.1. Phase I
6.1.1.2. Phase II
6.1.1.3. Phase III
6.1.1.4. Phase IV
6.2. Asia Pacific Clinical Trials Market Outlook, by Study Design, Value (US$ Bn), 2018 - 2030
6.2.1. Key Highlights
6.2.1.1. Interventional
6.2.1.2. Observational
6.2.1.3. Expanded Access
6.3. Asia Pacific Clinical Trials Market Outlook, by Indication, Value (US$ Bn), 2018 - 2030
6.3.1. Key Highlights
6.3.1.1. Autoimmune/Inflammation
6.3.1.1.1. Rheumatoid arthritis
6.3.1.1.2. Multiple Sclerosis
6.3.1.1.3. Osteoarthritis
6.3.1.1.4. Irritable Bowel Syndrome (IBS)
6.3.1.1.5. Others
6.3.1.2. Pain Management
6.3.1.2.1. Chronic Pain
6.3.1.2.2. Acute Pain
6.3.1.3. Oncology
6.3.1.3.1. Blood Cancer
6.3.1.3.2. Solid Tumors
6.3.1.3.3. Other
6.3.1.4. CNS Condition
6.3.1.4.1. Epilepsy
6.3.1.4.2. Parkinson's Disease (PD)
6.3.1.4.3. Huntington's Disease
6.3.1.4.4. Stroke
6.3.1.4.5. Traumatic Brain Injury (TBI)
6.3.1.4.6. Amyotrophic Lateral Sclerosis (ALS)
6.3.1.4.7. Muscle Regeneration
6.3.1.4.8. Others
6.3.1.5. Diabetes
6.3.1.6. Obesity
6.3.1.7. Cardiovascular
6.3.1.8. Others
6.4. Asia Pacific Clinical Trials Market Outlook, by Service Type, Value (US$ Bn), 2018 - 2030
6.4.1. Key Highlights
6.4.1.1. Protocol Designing
6.4.1.2. Site Identification
6.4.1.3. Patient Recruitment
6.4.1.4. Laboratory Services
6.4.1.5. Bioanalytical Testing Services
6.4.1.6. Clinical Trial Data Management Services
6.4.1.7. Others
6.4.2. BPS Analysis/Market Attractiveness Analysis
6.5. Asia Pacific Clinical Trials Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
6.5.1. Key Highlights
6.5.1.1. China Clinical Trials Market by Phase, Value (US$ Bn), 2018 - 2030
6.5.1.2. China Clinical Trials Market by Study Design, Value (US$ Bn), 2018 - 2030
6.5.1.3. China Clinical Trials Market by Indication, Value (US$ Bn), 2018 - 2030
6.5.1.4. China Clinical Trials Market by Service Type, Value (US$ Bn), 2018 - 2030
6.5.1.5. Japan Clinical Trials Market by Phase, Value (US$ Bn), 2018 - 2030
6.5.1.6. Japan Clinical Trials Market by Study Design, Value (US$ Bn), 2018 - 2030
6.5.1.7. Japan Clinical Trials Market by Indication, Value (US$ Bn), 2018 - 2030
6.5.1.8. Japan Clinical Trials Market by Service Type, Value (US$ Bn), 2018 - 2030
6.5.1.9. India Clinical Trials Market by Phase, Value (US$ Bn), 2018 - 2030
6.5.1.10. India Clinical Trials Market by Study Design, Value (US$ Bn), 2018 - 2030
6.5.1.11. India Clinical Trials Market by Indication, Value (US$ Bn), 2018 - 2030
6.5.1.12. India Clinical Trials Market by Service Type, Value (US$ Bn), 2018 - 2030
6.5.1.13. Southeast Asia Clinical Trials Market by Phase, Value (US$ Bn), 2018 - 2030
6.5.1.14. Southeast Asia Clinical Trials Market by Study Design, Value (US$ Bn), 2018 - 2030
6.5.1.15. Southeast Asia Clinical Trials Market by Indication, Value (US$ Bn), 2018 - 2030
6.5.1.16. Southeast Asia Clinical Trials Market by Service Type, Value (US$ Bn), 2018 - 2030
6.5.1.17. Rest of Asia Pacific Clinical Trials Market by Phase, Value (US$ Bn), 2018 - 2030
6.5.1.18. Rest of Asia Pacific Clinical Trials Market by Study Design, Value (US$ Bn), 2018 - 2030
6.5.1.19. Rest of Asia Pacific Clinical Trials Market by Indication, Value (US$ Bn), 2018 - 2030
6.5.1.20. Rest of Asia Pacific Clinical Trials Market by Service Type, Value (US$ Bn), 2018 - 2030
6.5.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Clinical Trials Market Outlook, 2018 - 2030
7.1. Latin America Clinical Trials Market Outlook, by Phase, Value (US$ Bn), 2018 - 2030
7.1.1. Key Highlights
7.1.1.1. Phase I
7.1.1.2. Phase II
7.1.1.3. Phase III
7.1.1.4. Phase IV
7.2. Latin America Clinical Trials Market Outlook, by Study Design, Value (US$ Bn), 2018 - 2030
7.2.1. Key Highlights
7.2.1.1. Interventional
7.2.1.2. Observational
7.2.1.3. Expanded Access
7.3. Latin America Clinical Trials Market Outlook, by Indication, Value (US$ Bn), 2018 - 2030
7.3.1. Key Highlights
7.3.1.1. Autoimmune/Inflammation
7.3.1.1.1. Rheumatoid arthritis
7.3.1.1.2. Multiple Sclerosis
7.3.1.1.3. Osteoarthritis
7.3.1.1.4. Irritable Bowel Syndrome (IBS)
7.3.1.1.5. Others
7.3.1.2. Pain Management
7.3.1.2.1. Chronic Pain
7.3.1.2.2. Acute Pain
7.3.1.3. Oncology
7.3.1.3.1. Blood Cancer
7.3.1.3.2. Solid Tumors
7.3.1.3.3. Other
7.3.1.4. CNS Condition
7.3.1.4.1. Epilepsy
7.3.1.4.2. Parkinson's Disease (PD)
7.3.1.4.3. Huntington's Disease
7.3.1.4.4. Stroke
7.3.1.4.5. Traumatic Brain Injury (TBI)
7.3.1.4.6. Amyotrophic Lateral Sclerosis (ALS)
7.3.1.4.7. Muscle Regeneration
7.3.1.4.8. Others
7.3.1.5. Diabetes
7.3.1.6. Obesity
7.3.1.7. Cardiovascular
7.3.1.8. Others
7.4. Latin America Clinical Trials Market Outlook, by Service Type, Value (US$ Bn), 2018 - 2030
7.4.1. Key Highlights
7.4.1.1. Protocol Designing
7.4.1.2. Site Identification
7.4.1.3. Patient Recruitment
7.4.1.4. Laboratory Services
7.4.1.5. Bioanalytical Testing Services
7.4.1.6. Clinical Trial Data Management Services
7.4.1.7. Others
7.4.2. BPS Analysis/Market Attractiveness Analysis
7.5. Latin America Clinical Trials Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
7.5.1. Key Highlights
7.5.1.1. Brazil Clinical Trials Market by Phase, Value (US$ Bn), 2018 - 2030
7.5.1.2. Brazil Clinical Trials Market by Study Design, Value (US$ Bn), 2018 - 2030
7.5.1.3. Brazil Clinical Trials Market by Indication, Value (US$ Bn), 2018 - 2030
7.5.1.4. Brazil Clinical Trials Market by Service Type, Value (US$ Bn), 2018 - 2030
7.5.1.5. Mexico Clinical Trials Market by Phase, Value (US$ Bn), 2018 - 2030
7.5.1.6. Mexico Clinical Trials Market by Study Design, Value (US$ Bn), 2018 - 2030
7.5.1.7. Mexico Clinical Trials Market by Indication, Value (US$ Bn), 2018 - 2030
7.5.1.8. Mexico Clinical Trials Market by Service Type, Value (US$ Bn), 2018 - 2030
7.5.1.9. Rest of Latin America Clinical Trials Market by Phase, Value (US$ Bn), 2018 - 2030
7.5.1.10. Rest of Latin America Clinical Trials Market by Study Design, Value (US$ Bn), 2018 - 2030
7.5.1.11. Rest of Latin America Clinical Trials Market by Indication, Value (US$ Bn), 2018 - 2030
7.5.1.12. Rest of Latin America Clinical Trials Market by Service Type, Value (US$ Bn), 2018 - 2030
7.5.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Clinical Trials Market Outlook, 2018 - 2030
8.1. Middle East & Africa Clinical Trials Market Outlook, by Phase, Value (US$ Bn), 2018 - 2030
8.1.1. Key Highlights
8.1.1.1. Phase I
8.1.1.2. Phase II
8.1.1.3. Phase III
8.1.1.4. Phase IV
8.2. Middle East & Africa Clinical Trials Market Outlook, by Study Design, Value (US$ Bn), 2018 - 2030
8.2.1. Key Highlights
8.2.1.1. Interventional
8.2.1.2. Observational
8.2.1.3. Expanded Access
8.3. Middle East & Africa Clinical Trials Market Outlook, by Indication, Value (US$ Bn), 2018 - 2030
8.3.1. Key Highlights
8.3.1.1. Autoimmune/Inflammation
8.3.1.1.1. Rheumatoid arthritis
8.3.1.1.2. Multiple Sclerosis
8.3.1.1.3. Osteoarthritis
8.3.1.1.4. Irritable Bowel Syndrome (IBS)
8.3.1.1.5. Others
8.3.1.2. Pain Management
8.3.1.2.1. Chronic Pain
8.3.1.2.2. Acute Pain
8.3.1.3. Oncology
8.3.1.3.1. Blood Cancer
8.3.1.3.2. Solid Tumors
8.3.1.3.3. Other
8.3.1.4. CNS Condition
8.3.1.4.1. Epilepsy
8.3.1.4.2. Parkinson's Disease (PD)
8.3.1.4.3. Huntington's Disease
8.3.1.4.4. Stroke
8.3.1.4.5. Traumatic Brain Injury (TBI)
8.3.1.4.6. Amyotrophic Lateral Sclerosis (ALS)
8.3.1.4.7. Muscle Regeneration
8.3.1.4.8. Others
8.3.1.5. Diabetes
8.3.1.6. Obesity
8.3.1.7. Cardiovascular
8.3.1.8. Others
8.4. Middle East & Africa Clinical Trials Market Outlook, by Service Type, Value (US$ Bn), 2018 - 2030
8.4.1. Key Highlights
8.4.1.1. Protocol Designing
8.4.1.2. Site Identification
8.4.1.3. Patient Recruitment
8.4.1.4. Laboratory Services
8.4.1.5. Bioanalytical Testing Services
8.4.1.6. Clinical Trial Data Management Services
8.4.1.7. Others
8.4.2. BPS Analysis/Market Attractiveness Analysis
8.5. Middle East & Africa Clinical Trials Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
8.5.1. Key Highlights
8.5.1.1. GCC Clinical Trials Market by Phase, Value (US$ Bn), 2018 - 2030
8.5.1.2. GCC Clinical Trials Market by Study Design, Value (US$ Bn), 2018 - 2030
8.5.1.3. GCC Clinical Trials Market by Indication, Value (US$ Bn), 2018 - 2030
8.5.1.4. GCC Clinical Trials Market by Service Type, Value (US$ Bn), 2018 - 2030
8.5.1.5. South Africa Clinical Trials Market by Phase, Value (US$ Bn), 2018 - 2030
8.5.1.6. South Africa Clinical Trials Market by Study Design, Value (US$ Bn), 2018 - 2030
8.5.1.7. South Africa Clinical Trials Market by Indication, Value (US$ Bn), 2018 - 2030
8.5.1.8. South Africa Clinical Trials Market by Service Type, Value (US$ Bn), 2018 - 2030
8.5.1.9. Rest of Middle East & Africa Clinical Trials Market by Phase, Value (US$ Bn), 2018 - 2030
8.5.1.10. Rest of Middle East & Africa Clinical Trials Market by Study Design, Value (US$ Bn), 2018 - 2030
8.5.1.11. Rest of Middle East & Africa Clinical Trials Market by Indication, Value (US$ Bn), 2018 - 2030
8.5.1.12. Rest of Middle East & Africa Clinical Trials Market by Service Type, Value (US$ Bn), 2018 - 2030
8.5.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Key player vs Phase/Indication Heatmap
9.2. Company Market Share Analysis, 2022
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Eli Lilly and Company
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Development
9.4.2. Syneos Health
9.4.2.1. Company Overview
9.4.2.2. Product Portfolio
9.4.2.3. Financial Overview
9.4.2.4. Business Strategies and Development
9.4.3. Pharmaceutical Product Development (PPD)
9.4.3.1. Company Overview
9.4.3.2. Product Portfolio
9.4.3.3. Financial Overview
9.4.3.4. Business Strategies and Development
9.4.4. Novo Nordisk A/S
9.4.4.1. Company Overview
9.4.4.2. Product Portfolio
9.4.4.3. Financial Overview
9.4.4.4. Business Strategies and Development
9.4.5. Icon plc.
9.4.5.1. Company Overview
9.4.5.2. Product Portfolio
9.4.5.3. Financial Overview
9.4.5.4. Business Strategies and Development
9.4.6. Charles River Laboratories
9.4.6.1. Company Overview
9.4.6.2. Product Portfolio
9.4.6.3. Financial Overview
9.4.6.4. Business Strategies and Development
9.4.7. Parexel International Corporation
9.4.7.1. Company Overview
9.4.7.2. Product Portfolio
9.4.7.3. Financial Overview
9.4.7.4. Business Strategies and Development
9.4.8. WuXi Apptec
9.4.8.1. Company Overview
9.4.8.2. Product Portfolio
9.4.8.3. Business Strategies and Development
9.4.9. Medpace Holdings, Inc.
9.4.9.1. Company Overview
9.4.9.2. Product Portfolio
9.4.9.3. Financial Overview
9.4.9.4. Business Strategies and Development
9.4.10. KCR Pharmaceuticals Pvt. Ltd.
9.4.10.1. Company Overview
9.4.10.2. Product Portfolio
9.4.10.3. Financial Overview
9.4.10.4. Business Strategies and Development
9.4.11. Pharmaceutical Solutions Industry Ltd. (PSI).
9.4.11.1. Company Overview
9.4.11.2. Product Portfolio
9.4.11.3. Financial Overview
9.4.11.4. Business Strategies and Development
9.4.12. Pfizer
9.4.12.1. Company Overview
9.4.12.2. Product Portfolio
9.4.12.3. Financial Overview
9.4.12.4. Business Strategies and Development
9.4.13. Thermo Fisher Scientific Inc.
9.4.13.1. Company Overview
9.4.13.2. Product Portfolio
9.4.13.3. Financial Overview
9.4.13.4. Business Strategies and Development
9.4.14. Sanofi SA
9.4.14.1. Company Overview
9.4.14.2. Product Portfolio
9.4.14.3. Financial Overview
9.4.14.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations
|
BASE YEAR |
HISTORICAL DATA |
FORECAST PERIOD |
UNITS |
|||
 |
2022 |
 |
2018 - 2022 |
 |
2023 - 2030 |
Value: US$ Million |
|
REPORT FEATURES |
DETAILS |
|
Phase Coverage |
|
|
Study Design Coverage |
|
|
Indication Coverage |
|
|
Service Type Coverage |
|
|
Geographical Coverage |
|
|
Leading Companies |
|
|
Report Highlights |
Key Market Indicators, Macro-micro economic impact analysis, Technological Roadmap, Key Trends, Driver, Restraints, and Future Opportunities & Revenue Pockets, Porter’s 5 Forces Analysis, Historical Trend (2019-2021), Market Estimates and Forecast, Market Dynamics, Industry Trends, Competition Landscape, Category, Region, Country-wise Trends & Analysis, COVID-19 Impact Analysis (Demand and Supply Chain) |
Quality assured
